Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Biosci Trends. 2019;13(3):282-283
Authors: Yao X, Wang L, Gao J
Abstract
Hepatocellular carcinoma (HCC) is a prevalent and refractory cancer in the world and very few drugs are available for the disease treatment currently. Programmed cell death protein-1 (PD-1) monoclonal antibodies including nivolumab and pembrolizumab has received accelerated approval for treatment of advanced HCC based on phase 1/2 clinical trials. However, the recently disclosed results of phase 3 clinical trials showed that both nivolumab and pembrolizumab as monotherapy failed to meet the primary objectives, which might overshadow the prospect of PD-1 inhibitors as monotherapy in treatment of advanced and unresectable HCC. The feasibility of PD-1 inhibitors in combination with other therapies or in other HCC settings requires further verification in the future.
PMID: 31327798 [PubMed - in process]
Source: BioScience Trends - Category: Biomedical Science Tags: Biosci Trends Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hepatocellular Carcinoma | Liver Cancer